Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A injection for cognitive dysfunction after brain injury
ChiCTR2400092753Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Huperzine A in cognitive disorder (CD) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Cognitive function score. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
Huperzine A
03
Conditions
cognitive disorder (CD)
Beyond the preview
Go deeper on ChiCTR2400092753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092753.